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Abstract: Short-chain fatty acids (SCFA) are bacterial metabolites that can be found in periodontal 
pockets. The expression of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1) 
within the epithelium pocket is considered to be a key event for the selective transmigration of 
leucocytes towards the gingival sulcus. However, the impact of SCFA on ICAM-1 expression by 
oral epithelial cells remains unclear. We therefore exposed the oral squamous carcinoma cell line 
HSC-2, primary oral epithelial cells and human gingival fibroblasts to SCFA, namely acetate, 
propionate and butyrate, and stimulated with known inducers of ICAM-1 such as interleukin-1-
beta (IL1β) and tumor necrosis factor-alfa (TNFα). We report here that butyrate but not acetate or 
propionate significantly suppressed the cytokine-induced ICAM-1 expression in HSC-2 epithelial 
cells and primary epithelial cells. The G-protein coupled receptor-43 (GPR43/ FFAR2) agonist but 
not the histone deacetylase inhibitor, trichostatin A, mimicked the butyrate effects. Butyrate also 
attenuated the nuclear translocation of p65 into the nucleus on HSC-2 cells. The decrease of ICAM-
1 was independent of Nrf2/HO-1 signaling and phosphorylation of JNK and p38. Nevertheless, 
butyrate could not reverse an ongoing cytokine-induced ICAM-1 expression in HSC-2 cells. Overall, 
these observations suggest that butyrate can attenuate cytokine-induced ICAM-1 expression in cells 
with epithelial origin. 
Keywords: butyric acid; periodontium; intercellular adhesion molecule-1; oral biology; epithelial 
cells; in vitro. 
 
1. Introduction 
Oral health requires the cellular immunity of the oral mucosal barrier that extends towards the 
periodontium to defend the tooth-bearing tissue against commensal microbes and other antigens of 
the oral cavity [1]. The junctional epithelium controls the transmigration of neutrophils towards the 
crevicular fluid by means of a tightly controlled expression of adhesion molecules, thereby defending 
microbiological antagonism in the periodontal tissue [2,3]. Thus, the increase of adhesion molecules 
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by inflammatory mediators has to be counterbalanced by local cues to control an excessive influx of 
cells of the innate immune system.  
The influx of cells is controlled by intercellular adhesion molecule-1 (ICAM-1), allowing the 
transmigration of leucocytes which express the corresponding lymphocyte function-associated 
antigen-1 and macrophage adhesion ligand-1 [4]. ICAM-1, being induced by inflammatory cues such 
as interleukin-1-beta (IL1β) and tumor necrosis factor-α (TNFα) [5], is expressed by the vascular 
endothelium and by the junctional epithelium [6], thus, facilitating transmigration of leukocytes 
across vascular endothelia and the invasion of the extracellular matrix [7]. Although ICAM-1 is 
consistently expressed by junctional epithelial cells in healthy gingiva and in pocket epithelium, it is 
not detectable on the majority of keratinocytes in the external gingival epithelium [6,8]. The question 
then arises, how is the expression of ICAM-1 in epithelial cells controlled? 
The increase of ICAM-1 expression by inflammatory cues is evidently well-documented. 
Inflammatory mediators including IL-6 and prostaglandin E2 increase ICAM-1 expression in human 
oral squamous cell carcinoma SCC4 cells in vitro [9,10]. Primary gingival epithelial cells increasingly 
express ICAM-1 upon inflammatory cytokines stimuli, namely, TNFα and interferon-γ [11]. Gingival 
fibroblasts also express ICAM-1 in response to inflammatory cytokines [12]. Nevertheless, the 
opposite effect, the down-regulation of ICAM-1, has not been conclusively defined. Down-regulation 
of ICAM-1 on bronchial epithelial cells has been observed with fenoterol, a β2-adrenoceptor agonist 
[13], and in retinal pigment epithelial cells with bezafibrate, a drug to treat hyperlipidemia [14]. 
However, little is understood about what decreases ICAM-1 expression in oral epithelial cells.  
Short-chain fatty acids (SCFA) are mainly produced by Gram-negative bacteria, being acetate, 
propionate, and butyrate the three most common molecules [15]. SCFA are found in the oral cavity, 
particularly in dental plaque and sites with periodontal disease [16,17]. Millimolar concentration of 
butyrate in the gingival crevicular fluid were correlated with gingival inflammation and periodontal 
pocket depth [18]. Anaerobic bacteria in subgingival plaques such as Porphyromonas gingivalis, 
Treponema denticola, Aggregatibacter actinomycetemcomitans, Prevotella intermedia and Fusobacterium 
nucleatum release SCFA, including butyrate [17]. Furthermore, butyrate from oral environment can 
cross the gingival barrier and potentially cause systemic inflammation and localized detrimental 
effects in the brain [19]. Taken together, it seems that butyrate and other SCFA are virulence factors 
in periodontal disease.  
Butyrate can activate the free fatty acid receptor-2 (FFAR2), also known as G-protein coupled 
receptor-43 (GPR43) [20], but also inhibit the histone deacetylase (HDAC) [21]. Using either of these 
mechanisms, butyrate reduces proliferation and induces apoptosis in gingival fibroblast [22–25], 
stimulates T-cell apoptosis [26] and osteoblast maturation [27], as well as pro-inflammatory cytokine 
release by neutrophils [28]. Butyrate also reduced integrin expression in Ca9-22 epithelial cells [23,29] 
and promoted autophagy [30]. The presence of SCFA in the infectious site attenuates the neutrophils 
response to A. actinomycetemcomitans as a result of the inhibition of specific isoforms of HDACs, 
namely, HDAC 1 and 3, but not activation of FFAR2 [31]. Recent findings suggest that butyrate 
disturbs gingival epithelial homeostasis and initiates expression of pro-inflammatory cytokine in 
vitro [32]. Thus, there is accumulating evidence suggesting that SCFA has detrimental effects on cells 
of the periodontium. However, with respect to the beneficial effects of butyrate on colitis [33,34], 
pathological bone loss [35], anti-microbial activity [36], and on a M1-to-M2 shift in macrophages [37–
39] it should not be ruled out that SCFA may also contribute to tissue homeostasis by modulation of 
ICAM-1. 
Butyrate markedly reduces ICAM-1 expression in the intestine of severely burned rats [40] and 
in IL1β-stimulated chondrocytes [41]. Butyrate also reduces the expression of ICAM-1 in LPS-
stimulated mouse glomerular mesangial and Caco-2 cells [42,43], and cytokine-induced ICAM-1 
expression in cultured endothelial cells [44]. Conversely, other studies showed that butyrate increases 
ICAM-1 in human gingival carcinoma cell line Ca9-22 [23,45], in acute myeloid leukemia cells [46] 
and endothelial cells [47,48]. Owing to these inconsistent results, it cannot be predicted whether 
butyrate or other SCFA change the expression of ICAM-1 in oral epithelia cells. The aim of this study 
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was thus to investigate the influence of SCFA on the expression of ICAM-1 in oral cells with epithelial 
origin and to unravel possible underlying signaling pathways. 
2. Results 
2.1. Cell Viability Upon SCFA Stimulation at Varying Concentrations 
In order to evaluate the impact of SCFA on cell viability, an MTT assay, reflecting the NAD(P)H-
dependent formazan production, was carried out. To this end, HSC-2 and gingival fibroblasts were 
exposed to different concentration of SCFA ranging from 1 mM to 100 mM (Table 1). In case of acetate 
and propionate a concentration from 1 to 10 mM did not affect the viability of HSC-2 and gingival 
fibroblasts (Table 1). With respect to butyrate, a concentration up to 30 mM was tolerated by both cell 
types without altering their viability. Together, these observations indicate that 10 mM of SCFA is 
non-cytotoxic and therefore a suitable concentration for the following experiments.  
Table 1. Cell viability of HSC-2 and gingival fibroblasts at varying concentrations of SCFA. 
Cell type HSC-2 Cell Line Gingival Fibroblasts 
Concentration Acetate Propionate Butyrate Acetate Propionate Butyrate 
100 mM 39.2 ± 5 46.4 ± 5.1 53.5 ± 5 12.5 ± 1.2 11.9 ± 1.5 10.1 ± 0.9 
30 mM 45.8 ± 5.9 56.6 ± 5.8 95.8 ± 6 69.8 ± 4.5 74.5 ± 2.1 94 ± 0.5 
10 mM 104.7 ± 6.1 113 ± 6.4 122.7 ± 6.5 96.3 ± 1.2 102.7 ± 1.2 122.3 ± 3.1 
1 mM 125 ± 7.0 136 ± 5.6 139 ± 7.7 125.3 ± 6.7 130.4 ± 0.5 135.5 ± 6.5 
HSC-2 cells and gingival fibroblasts exposed at different concentration of SFCA. Cell viability is 
represented by formazan production indicated in percentage of unstimulated controls ± SD. Cells 
maintained their viability with up to 10 mM of acetate and propionate, and up to 30 mM of butyrate. 
2.2. Butyrate But Not Acetate and Propionate Decrease the Expression of ICAM-1 in HSC-2 Cells 
Then, to examine the possible role of SCFA on ICAM-1 expression, the oral squamous cell 
carcinoma cell line HSC-2 and gingival fibroblasts were cultured for 12 h with and without acetate, 
propionate and butyrate. Subsequently, the cells were exposed for three hours to known inducers of 
ICAM-1, namely IL1β and TNFα. Butyrate exposure at 10 mM dampened down the robust cytokine-
induced ICAM-1 mRNA expression in HSC-2 cells (p = 0.03; Figure 1A) but not in gingival fibroblasts 
(Figure S1) or TR146 cells (Figure S2). In HSC-2 cells this suppression was dose-dependent (Figure 
1B) and independent of the type of cytokine (Figures S3). Acetate and propionate at 10 mM, however, 
failed to cause a significant suppression of IL1β- and TNFα-induced ICAM-1 expression (p > 0.05, 
Figure 1A). Western blot analysis confirmed the marked suppression of ICAM-1 by butyrate (Figure 
1C). Similarly, butyrate suppressed the cytokine-induced expression of ICAM-1 in primary oral 
epithelial cells (Figure 2). Then, and in order to validate these observations, we used another 
experimental setting using primary mouse macrophages [37–39]. Notably, butyrate was capable of 
inhibiting the LPS- and saliva-induced ICAM-1 expression in primary mouse macrophages (Figure 
3). Collectively, these results suggest that butyrate suppresses the robust cytokine-induced ICAM-1 
expression in HSC-2, primary oral epithelial cells and macrophages. 
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Figure 1. (A) Butyrate suppresses the cytokine-induced expression of ICAM-1 in HSC-2 cells. HSC-2 
were exposed for 24 h to 10 mM of acetate (C2), propionate (C3) and butyrate (C4), and then 
stimulated for three hours with 10 ng/mL of IL1β and TNFα. (+), indicates presence; (-), indicates 
absence. Data represent the mean change of ICAM-1 expression ± standard deviation. n = 3. Statistical 
analysis was based on ANOVA test with Tukey`s multiple comparisons correction and significant p-
values are indicated. (B) Butyrate suppresses the cytokine-induced increase of ICAM-1 in a dose-
dependent manner. HSC-2 cells were exposed to different concentrations of butyrate in the presence 
of IL1β and TNFα. Data represent the mean change of ICAM-1 expression ± standard deviation. n = 3 
(C) Butyrate attenuates the IL1β- and TNFα-induced expression of ICAM-1. HSC-2 cells were exposed 
to 10 mM of butyrate (C4) in the presence or absence of 10 ng/mL IL1β and TNFα. 
 
Figure 2. Butyrate suppresses the cytokine-induced increase of ICAM-1 in primary epithelial cells. 
Cells were exposed to 10 mM butyrate (C4) in the presence of 10 ng/mL IL1β and TNFα. (+), indicates 
presence; (-), indicates absence. Data represent the mean change of ICAM-1 expression ± standard 
deviation. n = 3. Statistical analysis was based on t-test and p-values are indicated.  
2.3. Activation of FFAR2 Can Mimic the Activity of Butyrate on ICAM-1 in HSC-2 Cells 
To distinguish between the dual activity of butyrate to activate the SCFA receptor FFAR2/GPR43 
[20] from the histone deacetylase inhibition [21], HSC-2 cells were pre-exposed to a FFAR2/GPR43 
agonist and to trichostatin A, an inhibitor of histone deacetylases. After 24 h of stimulation, IL1β and 
TNFα were added to induce ICAM-1. Similar to butyrate, the FFAR2/GPR43 agonist significantly 
reduced the cytokine-induced expression of ICAM-1 in HSC-2 cells (Figure 4). In contrast, trichostatin 
A failed to inhibit the ICAM-1 expression. Surprisingly, the FFAR2 agonist GLPG 0974 failed to 
reverse the effects of butyrate on ICAM-1 expression (data not shown). Overall, these observations 
partially suggest that the suppression activity of butyrate is due to an activation of FFARs rather than 
an inhibition of the histone deacetylase activity. 
2.4. Butyrate Inhibits the Nuclear Translocation of p65 on HSC-2 cells 
To explore a possible role of butyrate in inflammation, NF-kB p65 immunofluorescence was 
performed [49]. The presence of 10 mM of butyrate inhibited the IL1β- and TNFα-induced 
translocation of p65 protein into the nucleus in HSC-2 cells (Figure 5). Moreover, 10 mM of butyrate 
caused a 4-fold increase of β-arrestins-2 [50], known to be activated by FFAR2 receptor signaling, 
producing anti-inflammatory effects by inhibition of NF-κB [51,52]. This observation implies a 
suppression of the inflammatory activation by transcription factors triggered via NF-kB proteins that 
might involve Nrf2-HO1 signaling. However, blocking HO1 activity with SnPP failed to reverse the 
effects of butyrate on ICAM-1 expression in HSC2 cells (data not shown). Consistently, butyrate had 
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the suppression activity of butyrate on the LPS-induced ICAM-1 expression in primary macrophages 
(Figure S4). Since MAPK signaling cascade plays a key role in inflammation, we also examined the 
effect of butyrate on p38 and JNK expression to determine whether the suppressive activity of 
butyrate involves the MAPK pathway. Western blot analysis revealed that phosphorylation of p38 
and JNK being involved in ICAM-1 expression, was not affected by the addition of butyrate (Figure 
S5). Taken together, these observations indicate that the ICAM-1-suppressive activity of butyrate is 
independent of Nrf2-HO1 and MAPK pathway. 
 
Figure 3. Butyrate suppresses the LPS- and saliva-induced increase of ICAM-1 in primary mouse 
macrophages. Cells were exposed to 10 mM of butyrate (C4) in the presence of (A) 100 ng/mL of LPS 
and (B) 2% saliva. (+), indicates presence; (-), indicates absence. Data represent the mean change of 
ICAM-1 expression ± standard deviation. n = 4. Statistical analysis was based on Mann–Whitney U 
test and p-values are indicated. 
 
Figure 4. Activation of free fatty acid receptor-2 (FFAR2/GPR43) can mimic the activity of 10 mM of 
butyrate (C4) on ICAM-1 in HSC-2 cells. HSC-2 cells were exposed to a FFAR2/GPR43 agonist at 30 
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presence; (-), indicates absence. Data represent the mean change of ICAM-1 expression ± standard 




Figure 5. Butyrate suppresses NF-κB p65 translocation in inflamed HSC-2 cells. Butyrate at 10 mM 
attenuates the intracellular translocation of NF-κB p65 into the nucleus, induced by 10 ng/mL IL1β 
and TNFα in HSC-2. (wo), without. Representative immunofluorescence at 40x.  
2.5. Butyrate Cannot Reverse the Acute Expression Levels of ICAM-1 in HSC-2 Cells 
In the previous experimental setting, HSC-2 cells were exposed to butyrate for 24 h, before the 
incubation with IL1β and TNFα, simulating a prophylactic effect of butyrate. To investigate the 
possible role of butyrate in dampening the acute ICAM-1 expression, HSC-2 cells were exposed to 
IL1β and TNFα for 1 h and then butyrate was added for another 3 h. In this setting, butyrate failed to 
modulate the ICAM-1 expression in HSC-2 cells suggesting that butyrate can prevent but not reverse 
an ongoing ICAM-1 expression in inflammatory conditions (Figure 6). Moreover, three hours of pre-
exposure of HSC-2 cells with butyrate also failed to reduce the IL1β and TNFα-induced increase of 
ICAM-1, suggesting that a longer period of pre-incubation with butyrate is critical to obtain a   
ICAM-1 modulation [53]. 
 
Figure 6. Butyrate cannot reverse expression levels of ICAM-1 in HSC-2 cells. HSC-2 cells were 
exposed to 10 ng/mL IL1β and TNFα for 1 h before 10 mM of butyrate (C4) was added for another 3 
h. In this setting, butyrate FFAR2/GPR43 agonist and trichostatin A (TSA) failed to modulate the 
ICAM-1 expression in HSC-2 cells. (+), indicates presence; (-), indicates absence. Data represent the 
mean change of ICAM-1 expression ± standard deviation. n = 3. Statistical analysis was based on t-
test.  
3. Discussion 
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Our findings showed that butyrate but not acetate or propionate attenuates the cytokine-
induced ICAM-1 expression in oral squamous cells. This effect was consistent in all experiments 
performed, being confirmed at the transcriptional and the protein levels. The changes of ICAM-1 
expression were further confirmed with primary oral epithelial cells and macrophages, while 
gingival fibroblasts failed to respond to butyrate. These observations raise the hypothesis that 
butyrate can modulate epithelial cell responses in the inflamed periodontium and thereby possibly 
influencing the ICAM-1-dependent transmigration of leucocytes and immune cells. It seems 
reasonable to relate the production of butyrate by periodontal pathogens with the severity of 
periodontitis. In this sense, a possible mechanism might be that the reduction of ICAM-1 expression 
lowers the influx of leukocytes to the inflamed tissue thereby hampering the immune system to tackle 
bacterial invasion. Nevertheless, further research is required to elucidate the precise role of butyrate 
in the periodontal tissues under different in vitro conditions. 
Our research supports the role of butyrate to reduce ICAM-1 expression as observed in the 
intestine of burned rats [40], stimulated chondrocytes [41], glomerular mesangial cells [42], colon cancer 
cells [43], and endothelial cells [44]. These observations together with our findings are, however, in 
contrast to those showing that butyrate increases ICAM-1 in gingival carcinoma cells [23,45], leukemia 
cells [46] and endothelial cells [47,48]. Furthermore, high concentrations of butyrate provoke apoptosis 
in inflamed human gingival fibroblasts and periodontal destruction [25,29]. The testing of acetate and 
propionate was also hampered by the higher toxicity compared to butyrate. Surprising was that 
although acetate and propionate are agonist for the FFAR2/GPR43, only butyrate caused the robust and 
significant suppression of ICAM-1 expression [52]. Moreover, blocking of FFAR2/GPR43 by the 
antagonist GLPG 0974 failed to reverse the effects of butyrate on ICAM-1 expression. This raises the 
question whether the FFAR3/GPR41 is mediating the activity of butyrate [54]. Thus, further research is 
necessary to unravel the underlying mechanism at the receptor level. 
The FFAR2 receptor activates β-arrestins-2, producing anti-inflammatory effects by inhibition of 
NF-κB [51,52] and ICAM-1 has a NFκB binding prompter region [55]. In support of this potential 
mechanism, we show that β-arrestins-2 is increased by butyrate in HSC-2 cells. Hence, the blocking 
of NFκB nuclear translocation likely reduces ICAM-1 expression, being in line with our main 
observations on the regulation of ICAM-1 by butyrate. The reason why TR146 cells and gingival 
fibroblasts failed to respond to butyrate may be explained by their low increase of ICAM-1 expression 
in response to inflammatory cytokines. However, also short-time exposure of HSC-2 cells to butyrate 
had no considerable effect suggesting that not enough β-arrestins-2 is produced to reduce NF-κB 
signaling. Certainly, the role of butyrate to change β-arrestins-2 expression and the involvement in 
ICAM-1 expression in HSC-2 cells should be investigated. Although many questions remain open, 
the present data clearly show that butyrate can prevent the cytokine-induced ICAM-1 expression in 
oral squamous cell carcinoma cells, primary oral epithelial cells and macrophages. 
To better understand the underlying molecular mechanisms, the Nrf2-HO1 pathway was 
investigated. Butyrate uses the Nrf2/HO-1 pathway to ameliorate diabetic nephropathy [56], to 
regulate Th17/Treg cell balance [57] and to protects against high-fat diet-induced oxidative stress in 
rat liver [58]. There is also evidence that butyrate inhibits the acute lung injury in mice by regulating 
the NFκB signaling pathway [59]. Moreover, Nrf2-HO1 signaling is linked to ICAM-1 expression in 
a mouse atherosclerosis model [60], in THP-1 macrophages [61], and HaCaT cells [62]. However, in 
the present study, SnPP blocking HO1 activity could not reverse the inhibition of butyrate in ICAM-
1 expression. Indeed, macrophages from Nrf2 knockout and wildtype mice showed similar inhibition 
of ICAM-1 expression. Even though Nrf2-HO1 signaling was a strong candidate to mediate the effects 
of butyrate, this mechanism is presumably not relevant for the observations we have reported here. 
Furthermore, butyrate failed to reduce the phosphorylation of p38 and JNK, both major signaling 
molecules driving NFκB signaling and ICAM-1 expression in HSC-2 cells suggesting that other 
pathways than Nrf2-HO1 and MAPK signaling are relevant to explain the strong inhibition of ICAM-
1 by butyrate [62–64]. 
Are the present findings clinically relevant? To answer that question, it is worth mention that 
the commensal bacteria that induce a low-grade inflammatory state in the junctional epithelium are 
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likely the triggers of ICAM-1 expression and neutrophils migration [7]. Thus, there is strong ICAM-
1 staining of the junctional epithelium in both clinically healthy and inflamed tissue [2], even though 
soluble ICAM-1 shed into the gingival crevicular fluid was higher in patients with inflammation [63]. 
Considering that mice deficient in ICAM-1 have impaired immune function and decreased 
inflammatory response [64], a decrease of ICAM-1 in epithelial cells caused by butyrate might 
weaken the innate immunity and thus the local defense of the periodontium. Regarding the role of 
ICAM-1 in macrophages, this also remains controversial. ICAM-1 deficiency increases M2 
macrophage polarization and suppress tumor metastasis [65], but others reported that 
downregulation of ICAM-1 in RAW264.7 macrophages resulted in inflammatory M1 polarization 
[66]. Therefore, the possible implication of ICAM-1 expression in macrophages and its regulation by 
butyrate in periodontal tissue homeostasis remains to be determined. 
This study has limitations that need to be acknowledged. Our finding that butyrate protects cells 
from cytokine-induced ICAM-1 expression in oral squamous cell carcinoma cells in vitro does not 
necessarily explain the in vivo situation. Notably, butyrate failed to diminish an ongoing ICAM-1 
expression in HSC-2 cells. It would be interesting to determine the impact of SCFA on periodontitis 
by means of in vivo models. For example, it can be suggested to study the role of epithelial ICAM-1 
on healthy periodontium, the impact of the SCFA receptors in this context, and whether butyrate 
produced by periodontal pathogens plays a role in pathogenesis of periodontitis. Furthermore, 
exciting questions about how SCFA from non-digestible nutritional fibers metabolized by gut 
bacteria [67] can enter the bloodstream and elicit systemic effects should be addressed. An optimized 
diet rich in fibers can reduce gingival and periodontal inflammation in humans [68,69]. This 
observation inspires further research towards a possible beneficial role of butyrate on ICAM-1 
expression in the periodontal tissue. Moreover, future studies should be performed in FFAR2 and 
FFAR3-deficient mice asking if butyrate can prevent inflammatory osteolysis [70,71], and if yes, if 
this effect also involves the blocking of the histone deacetylase [72,73]. 
In conclusion, our findings that butyrate modulates the inflammatory response in oral epithelial 
cells by decreasing ICAM-1 expression provide a new step towards understanding the effect of 
ICAM-1 under inflammatory conditions. These in vitro data may inspire future research on the 
mechanisms by which diet, microbiota and other factors influence the immune system and, 
consequently, the development of inflammatory and infectious diseases. 
4. Material and Methods 
4.1. Cell Culture 
Human oral epithelial carcinoma cells HSC-2 and TR146 were kindly provided by Prof. Rausch-
Fan from Medical University of Vienna, Vienna, Austria. Gingival fibroblasts and primary epithelial 
cells were obtained from human gingiva harvested from extracted third molars of patients who had 
given informed and written consent. Gingival fibroblasts were prepared by explant cultures. The 
epithelium was separated from the underlying connective tissue after overnight dispase II (2.4 U/mL; 
Roche, Mannheim, Germany) treatment, and preparation of single-cell suspension by means of 
trypsin (Lonza, Walkersville, MD) digestion at 37 °C for 10 min. Epithelial cells were expanded in 
growth medium-2 (KGM-2; Lonza, Basel, Switzerland). The Ethics Committee of the Medical 
University of Vienna (EK NR 631/2007, 19.03.2019) Vienna, Austria, approved this protocol. Cell lines 
and gingival fibroblasts were cultured in Dulbecco’s modified Eagle medium (DMEM, Invitrogen 
Corporation, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (Invitrogen Corporation, 
Carlsbad, CA, USA) and antibiotics (Invitrogen Corporation, Carlsbad, CA, USA) at 37 °C, 5% CO2, 
and 95% humidity. Gingival epithelial cells were cultured in keratinocyte growth medium-2 (KGM-
2; Lonza, Basel, Switzerland) at 37 °C, 5% CO2, and at 95% relative humidity. Cells were seeded in 
growth medium at a concentration of at least 30,000 cells/cm2 onto culture dishes one day prior to 
stimulation. Serum-free conditions were used during cell stimulation. For the isolation and culture 
of murine bone marrow-derived macrophages, BALB/c mice (Animal Research Laboratories, 
Himberg, Austria) of 6–8 weeks old were purchased. Bone marrow cells were collected from the 
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femora and tibiae and grown for 5 days in Minimum Essential Medium Eagle-Alpha Modification 
(αMEM, Invitrogen Corporation, Carlsbad, CA, USA), supplemented with 10% fetal calf serum and 
antibiotics, supplemented with 20 ng/mL macrophage colony-stimulating factor (M-CSF; ProSpec-
Tany TechnoGene Ltd., Rehovot, Israel). For selected experiments, cells from Nrf2 knockout mice and 
the respective wildtype controls were used (Prof. Florian Gruber, Department of Dermatology, 
Medical University of Vienna, Vienna, Austria). 
4.2. Viability Assay 
Epithelial HSC-2 cells and gingival fibroblasts were incubated with different concentrations of 
acetate, propionate and butyrate (Sigma-Aldrich, St. Louis, MO, USA) or serum-free medium in 96-
well plates (CytoOne, Starlab International, Hamburg, Germany). After 24 h, a final concentration of 
0.5 mg/mL of a MTT - 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide – (Sigma-
Aldrich, St. Louis, MO, USA) solution was added to each well of the microtiter plate for 3 h at 37°C. 
After medium removal, formazan crystals were solubilized with dimethyl sulfoxide. Assessment of 
optical density was carried out for 570 nm. Absolute numbers of optical density in the treatment 
groups were expressed and presented as percentage of unstimulated controls ± standard deviation. 
4.3. Cell Stimulation 
Based on the findings from the viability assay, stimulation of HSC-2 cells and gingival fibroblasts 
was performed with 10 mM of acetate, propionate and butyrate. As a basic setting for the 
experiments, cells were exposed to SCFA for 24 h in serum-free medium before the addition of 10 
ng/mL IL1β and TNFα (ProSpec-Tany TechnoGene Ltd., Rehovot, Israel) for another three hours, 
after that gene expression analysis of ICAM-1 was performed. Likewise, the oral squamous cell 
carcinoma cell line TR146 was exposed to butyrate in the same conditions of HSC-2. Macrophages 
were exposed to SCFA for 24 h in growth medium before the addition of LPS (100 ng/mL, LPS from 
Escherichia coli 0111: B4; Sigma-Aldrich, St. Louis, MO, USA) or 2% of sterile pooled human saliva 
[74] for another three hours. For dose-response experiments in HSC-2 cells, concentrations of 1, 10, 
30 and 100 mM of butyrate were used. HSC-2 cells were further exposed to GPR43 (FFAR2) agonist 
(Merck KGaA, Darmstadt, Germany) at 30µM and the histone deacetylase inhibitor trichostatin A at 
10 nM (Sigma-Aldrich, St. Louis, MO, USA) for 24 h before inflammation was induced accordingly. 
In another series of experiments, HSC-2 cells were exposed to IL1β and TNFα for 1 h followed by the 
exposure to 10 mM butyrate for three hours, or exposed to butyrate either alone or in the presence of 
tin protoporphyrin IX dichloride (SnPP; Sigma-Aldrich, St. Louis, MO, USA) at a concentration of 
10 µM. We have included a rescue experiment by using the inhibitor of FFAR2 named GLPG 0974 at 
10µM (Tocris Bioscience™, Abingdon, UK). 
4.4. qRT-PCR Analysis 
ExtractMe total RNA kit (Blirt S.A., Gdańsk, Poland) was used for RNA isolation. Reverse 
transcription was then performed by means of SensiFASTTM cDNA (Bioline, London, UK). For 
polymerase chain reaction, SensiFASTTM SYBR ROX Kit (Bioline, London, UK) on a Real-Time PCR 
Detection System (Bio-Rad Laboratories, Hercules, CA, USA) was carried out. Primer sequences used 
are described in Table 2. The mRNA levels were calculated by normalizing to the housekeeping gene 
GAPDH using the ΔΔCt method. 
Table 2. Primer sequences. 
Primer  Sequence Forward Sequence Reverse 
hICAM-1 cct tcc tca ccg tgt act gg agc gta ggg taa ggt tct tgc 
hARRB2  caa ctc cac caa gac cgt caa ga ttc gag ttg agc cac agg aca ctt 
hGAPDH aag cca cat cgc tca gac ac gcc caa tac gac caa atc c 
hActin cca acc gcg aga aga tga cca gag gcg tac agg gat ag  
mICAM-1 gtg atg ctc agg tat cca tcc a cac agt tct caa agc aca gcg  
mGAPDH aac ttt ggc att gtg gaa gg gga tgc agg gat gat gtt ct 
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mActin cta agg cca acc gtg aaa ag acc aga ggc ata cag gga ca 
4.5. Western Blot 
After stimulation with butyrate for 24 h and the inflammatory cytokines IL1β and TNFα for 
another three hours, HSC-2 cells were extracted with SDS buffer and inhibitors of protease 
(PhosSTOP with cOmplete; Sigma-Aldrich, St. Louis, MO, USA), divided by SDS-PAGE and 
transferred onto nitrocellulose membranes (Whatman, GE Healthcare, General Electric Company, 
Fairfield, CT, USA). Thereafter, membranes were submitted to blocking process for 2 h and exposed 
to the first antibodies (mouse ICAM-1 G-5 and actin C-2 both at 200 ng/mL; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) for 24 h. In another series, HSC-2 cells were exposed to butyrate 
for 24 h and to the cytokines for 30 min before exposed to antibodies against phosphorylated and 
complete p38 and c-Jun N terminal protein kinase MAPK (both Cell Signaling Technologies, Danvers, 
MA, USA). Then, proteins were detected by the appropriate HRP-conjugated secondary antibody at 
40 ng/mL (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Subsequently, chemiluminescence 
detection (Clarity ECL Western Blot Substrate kit, Bio-Rad Laboratories, Hercules, CA, USA) was 
performed with a ChemiDoc MP System (Bio-Rad Laboratories, Hercules, CA, USA). 
4.6. Immunofluorescence 
Immunofluorescent analysis was performed on HSC-2 cells plated onto Millicell® EZ slides 
(Merck KGaA, Darmstadt, Germany) treated with 10 mM of butyrate overnight and then exposed to 
IL1β and TNFα for 30 min. Cells were fixed in 4% paraformaldehyde and blocked in 1% BSA and 
0.1% Triton in buffered saline before being incubated with nuclear factor kappa B (NF-κB) p65 
antibody (25 ng/mL, rabbit, Cell Signaling Technology, MA, USA) overnight at 4 °C. After washing, 
Alexa Fluor 488 secondary antibody (4 µg/mL; anti-rabbit, Cell Signaling Technology, MA, USA) was 
applied for 1 h at room temperature. Glass slides were mounted and images were captured at 40x 
under a Zeiss Axiovert 200 M fluorescent microscope (Carl Zeiss AG, Oberkochen, Germany). 
4.7. Statistical Analysis 
All experiments were repeated at least three times. Bars show the mean and standard deviation 
of the data from all independent experiments. Normality of the data was assessed using the Shapiro-
Wilk test. Statistical analysis was based on t-test and ANOVA or Mann–Whitney U test depending 
on the distribution of the data. Analyses were performed using Prism v7 (GraphPad Software, La 
Jolla, CA, USA). Significance was set at p < 0.05. 
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